Releases Details

Filing of Form 8-K

Jan 29, 2024
RNS Number : 1340B
MaxCyte, Inc.
29 January 2024
 

 

 

 

MaxCyte announces filing of Form 8-K

 

ROCKVILLE, MD, January 29, 2024 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announces that it has filed a Form 8-K with the SEC announcing the departure of Dr. Cenk Sumen as Chief Scientific Officer. Dr. Sumen will maintain a relationship with the Company as a member of MaxCyte's Scientific Advisory Board.

 

A copy of the Form 8-K is available to view on the SEC's website at www.sec.gov and has also been posted to the "SEC filings" page of the Company's website, https://investors.maxcyte.com/.

 

About MaxCyte

 

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

 

MaxCyte Contacts:

 

US IR Adviser 

Gilmartin Group 

David Deuchler, CFA 

+1 415-937-5400 

ir@maxcyte.com 

 

Nominated Adviser and Joint Corporate Broker 

Panmure Gordon 

Emma Earl / Freddy Crossley 

Corporate Broking 

Rupert Dearden 

 

 

+44 (0)20 7886 2500 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

 

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUWARRSAUAUUR